The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome

Marvin Kummer; Ibrahim El-Battrawy; Thorsten Gietzen; Uzair Ansari; Michael Behnes; Siegfried Lang; Xiaobo Zhou; Martin Borggrefe; Ibrahim Akin

doi:10.3389/fphar.2020.00681

The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome

Front Pharmacol. 2020 May 14:11:681. doi: 10.3389/fphar.2020.00681. eCollection 2020.

Authors

Marvin Kummer^{1

2}, Ibrahim El-Battrawy^{1

2}, Thorsten Gietzen^{1

2}, Uzair Ansari¹, Michael Behnes¹, Siegfried Lang^{1

2}, Xiaobo Zhou^{1

2}, Martin Borggrefe^{1

2}, Ibrahim Akin^{1

2}

Affiliations

¹ First Department of Medicine, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany.
² DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany.

Abstract

Background: Takotsubo syndrome (TTS) and acute coronary syndrome (ACS) patients have a similar mortality rate. In this study, we sought to determine the short- and long-term outcome of TTS patients as compared to ACS patients both treated with beta-blockers.

Objectives: In the present study we described the data of 5 years of follow up of 103 TTS and 422 ACS patients both treated with beta-blockers.

Methods: Data from TTS patients were included retrospectively and prospectively, ACS patients were included retrospectively. All retrospectively included patients have been followed up for 5 years. The end point in this study was the occurrence of death.

Results: TTS affected significantly more women (87.4%) than ACS (34.6%) (p < 0.01). TTS patients suffered significantly more often from thromboembolic events (14.6% versus 2.1%; p < 0.01) and cardiogenic shock (11.9% versus 3.6%; p < 0.01) than the ACS group. TTS patients had a significantly higher long-term mortality (within 5 years) as compared to ACS patients (17.5% versus 3.6%) (p < 0.01). Patients of the TTS group compared to the ACS group did not benefit from combination of beta-blockers and ACE-inhibitors in terms of long-term mortality (p < 0.01). As we compare TTS patients who were treated with beta-blockers and ACE-inhibitors versus single use of beta-blockers there was no difference in long-term mortality (p = 0.918).

Conclusion: TTS patients had a significantly higher long-term mortality (within 5 years) than patients with an ACS.

Keywords: Takotsubo syndrome (TTS); ace-inhibitors; acute coronary syndrome; beta-blockers; long-term mortality.